Lauren Carsten, NP
Payments from drug & device makers
Across 167 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$296
- AbbVie$293
- Boehringer Ingelheim$273
- Amgen$262
- Lilly USA, LLC$211
- Pfizer$153
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,623100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $296 |
| AbbVie | 25 | $293 |
| Boehringer Ingelheim | 18 | $273 |
| Amgen | 16 | $262 |
| Lilly USA, LLC | 14 | $211 |
| Pfizer | 9 | $153 |
| Abbott | 6 | $111 |
| Teva Pharmaceuticals USA, Inc. | 3 | $94 |
| AstraZeneca | 7 | $94 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Optinose US, Inc. | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Tris Pharma Inc | 3 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Johnson & Johnson | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Noven Therapeutics, LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| GSK | 2 | $27 |
| Merck | 2 | $27 |
| Bayer | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Gilead | 1 | $12 |
| Organon | 1 | $9 |
How this compares
$2,623 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $89,407 |
| OzempicSemaglutide | 66 | $78,008 |
| FarxigaDapagliflozin Propanediol | 54 | $61,909 |
| MounjaroTirzepatide | 31 | $38,858 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $33,145 |
| RybelsusSemaglutide | 15 | $28,125 |
| XareltoRivaroxaban | 26 | $27,957 |
| JardianceEmpagliflozin | 24 | $27,310 |
| TrulicityDulaglutide | 22 | $27,146 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $26,924 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,692 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $9,942 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $7,008 |
| Praluent PenAlirocumab | 14 | $6,633 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $6,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $296 | $106,13381 claims |
| PfizerEliquis | $153 | $89,407105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $211 | $66,00453 claims |
| AstraZenecaFarxiga | $94 | $61,90954 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $40 | $33,14516 claims |
| Johnson & JohnsonXarelto | $40 | $27,95726 claims |
| Boehringer IngelheimJardiance | $273 | $27,31024 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $4,126289 claims |
| AbbVieSynthroid | $293 | $1,05121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Irmo
- Hailey AtkinsonIrmo$24K
- Stefanie GunnIrmo$13K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.